The biotech industry is at a crossroads, grappling with the challenges and expectations set by cell therapies. Oncology-focused treatments that once held great promise are now facing a reality check, prompting many companies to reevaluate their focus on autoimmune diseases. As expectations align
In a significant expansion of its life sciences portfolio, global science and technology leader Merck has announced a definitive agreement to purchase Mirus Bio for a staggering $600 million. Mirus Bio, a pioneering life sciences company, specializes in developing transfection reagents, a
The battle against cancer is one that has engaged the global medical community for decades, and with the emergence of Chimeric Antigen Receptor (CAR) T-cell therapy, we stand on the precipice of a significant revolution in the way cancer is treated. This immunotherapy transforms a patient's own
Introduction Retro Biosciences, a pioneering biotech company, has embarked on an ambitious journey to extend human lifespan by a decade through innovative approaches to combat cellular aging. Its strategic partnership with Multiply Labs, a firm celebrated for advanced automation and robotic
The relentless progress of medical technology regularly unlocks new arenas in the battle against disease, with one of the most notable being the potent capabilities of Natural Killer (NK) cell therapies. As critical members of the immune system, NK cells have become the cornerstone of an innovative
Multiple myeloma (MM), a cancer that attacks the plasma cells in bone marrow, often evades cure, pushing scientists to constantly search for breakthrough therapies. Chimeric Antigen Receptor (CAR) T cell therapy represents one of the most innovative and promising strategies against relapsed MM. Its
